Certolizumab pegol inj 1mg
Products billed under this code include Cimzia.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cimzia.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cimzia | UCB, Inc. | 50474-0700-62 | 400 | $1,256.00 |
| Cimzia | UCB, Inc. | 50474-0710-79 | 400 | $1,256.00 |
| Cimzia | UCB, Inc. | 50474-0710-81 | 1200 | $3,768.00 |
| Cimzia | UCB, INC. | 50474-0750-10 | 200 | $628.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $3.14 | −$0.304 | 1 MG | Certolizumab pegol inj 1mg | v1, posted September 17, 2026 |
| 3Q26 | $3.444 | −$0.346 | 1 MG | Certolizumab pegol inj 1mg | v1, posted September 15, 2026 |
| 2Q26 | $3.79 | −$0.077 | 1 MG | Certolizumab pegol inj 1mg | v1, posted September 15, 2026 |
| 1Q26 | $3.867 | −$0.046 | 1 MG | Certolizumab pegol inj 1mg | v1, posted September 15, 2026 |
| 4Q25 | $3.913 | −$0.573 | 1 MG | Certolizumab pegol inj 1mg | v1, posted September 8, 2026 |
| 3Q25 | $4.486 | +$0.502 | 1 MG | Certolizumab pegol inj 1mg | v1, posted March 10, 2026 |
| 2Q25 | $3.984 | +$0.086 | 1 MG | Certolizumab pegol inj 1mg | v1, posted March 10, 2026 |
| 1Q25 | $3.898 | −$0.754 | 1 MG | Certolizumab pegol inj 1mg | v1, posted December 19, 2025 |
| 4Q24 | $4.652 | +$0.196 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 11, 2025 |
| 3Q24 | $4.456 | −$0.168 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 11, 2025 |
| 2Q24 | $4.624 | −$0.192 | 1 MG | Certolizumab pegol inj 1mg | v1, posted March 11, 2025 |
| 1Q24 | $4.816 | −$0.084 | 1 MG | Certolizumab pegol inj 1mg | v1, posted December 19, 2024 |
| 4Q23 | $4.90 | −$0.173 | 1 MG | Certolizumab pegol inj 1mg | v1, posted October 10, 2024 |
| 3Q23 | $5.073 | +$0.102 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 5, 2024 |
| 2Q23 | $4.971 | −$0.09 | 1 MG | Certolizumab pegol inj 1mg | v1, posted February 23, 2024 |
| 1Q23 | $5.061 | −$0.349 | 1 MG | Certolizumab pegol inj 1mg | v1, posted December 6, 2023 |
| 4Q22 | $5.41 | −$0.171 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 22, 2023 |
| 3Q22 | $5.581 | −$0.057 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 9, 2023 |
| 2Q22 | $5.638 | −$0.637 | 1 MG | Certolizumab pegol inj 1mg | v1, posted December 14, 2022 |
| 1Q22 | $6.275 | +$0.003 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 8, 2022 |
| 4Q21 | $6.272 | −$0.251 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 2, 2022 |
| 3Q21 | $6.523 | −$1.553 | 1 MG | Certolizumab pegol inj 1mg | v1, posted June 2, 2022 |
| 2Q21 | $8.076 | −$0.106 | 1 MG | Certolizumab pegol inj 1mg | v1, posted March 1, 2022 |
| 1Q21 | $8.182 | – | 1 MG | Certolizumab pegol inj 1mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.